The effect of azilsartan medoxomil on the variability of home blood pressure and diabetic vascular complications in patients with type 2 diabetes

The effect of azilsartan medoxomil on the variability of home blood pressure and diabetic vascular complications in patients with type 2 diabetes - Azilsartan and blood pressure variability in T2DM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016875

Enrollment

100

Registered

2015-03-23

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients with hypertension

Interventions

Switching from ARBs other than azilsartan to azilsartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients with hypertension who are receiving ARBs other than azilsartan

Exclusion criteria

Exclusion criteria: Patients who are already taking azilsartan treatment Patients with aliskiren Patients with active infectious diseases, malignant diseases, severe liver dysfunction and/or renal dysfunction Pregnant women Patients who have difficulty in understanding the protocol of the present study such as dementia or unconsciousness Patients whose anti-hypertensive agents were changed within 3 months prior to enrollment

Design outcomes

Primary

Measure	Time frame
The change of variability in home blood pressure at 3 months after administration of azilsartan	—

Secondary

Measure	Time frame
The change of albuminuria at 3 months after administration of azilsartan	—

Countries

Japan

Contacts

Public ContactRyotaro Bouchi

Tokyo Medical and Dental University Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences

bouchi.mem@tmd.ac.jp03-3813-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026